These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1569 related items for PubMed ID: 15625982

  • 1. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME.
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [Abstract] [Full Text] [Related]

  • 2. Effect of NIH-IV prostatitis on free and free-to-total PSA.
    Stancik I, Lüftenegger W, Klimpfinger M, Müller MM, Hoeltl W.
    Eur Urol; 2004 Dec; 46(6):760-4. PubMed ID: 15548444
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA, Oguz O, Olgun A, Seçkin B, Ilgan S, Hasimi A, Salih M, Peker F, Kutluay T.
    Ann Clin Lab Sci; 2002 Dec; 32(1):22-30. PubMed ID: 11848613
    [Abstract] [Full Text] [Related]

  • 4. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M, Jung K, Elgeti U, Brux B, Sinha P, Schnorr D, Loening SA.
    Anticancer Res; 2000 Dec; 20(6D):4997-5001. PubMed ID: 11326657
    [Abstract] [Full Text] [Related]

  • 5. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH, Magnabosco WJ, Mauad EC, Carvalho AL.
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [Abstract] [Full Text] [Related]

  • 6. Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients.
    Battikhi MN.
    Prostate Cancer Prostatic Dis; 2003 Dec; 6(3):256-60. PubMed ID: 12970732
    [Abstract] [Full Text] [Related]

  • 7. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
    Chun FK, Perrotte P, Briganti A, Benayoun S, Lebeau T, Ramirez A, Lewinshtein DJ, Valiquette L, Guay JP, Karakiewicz PI.
    BJU Int; 2006 Jul; 98(1):50-3. PubMed ID: 16831142
    [Abstract] [Full Text] [Related]

  • 8. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW, Liu G, Sheng BW.
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [Abstract] [Full Text] [Related]

  • 9. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C, Cammann H, Deger S, Schrader M, Meyer HA, Miller K, Lein M, Jung K.
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [Abstract] [Full Text] [Related]

  • 10. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P.
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [Abstract] [Full Text] [Related]

  • 11. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H, Kazerouni F, Sanadizade M, Sanadizade J, Kamalian N, Jalali M, Rahbar K, Karimi K.
    Urol J; 2010 Jun 10; 7(2):99-104. PubMed ID: 20535696
    [Abstract] [Full Text] [Related]

  • 12. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K.
    Cancer; 2005 Sep 01; 104(5):993-1003. PubMed ID: 16007682
    [Abstract] [Full Text] [Related]

  • 13. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K, Hoesel W, Reiche J, Deger S, Kramer J, Loening SA, Lein M, Stephan C.
    Urology; 2007 Feb 01; 69(2):320-5. PubMed ID: 17320672
    [Abstract] [Full Text] [Related]

  • 14. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, Babaian R, Childs SJ, Stamey T, Fritsche HA, Sokoll L, Chan DW, Thiel RP, Cheli CD.
    J Urol; 2003 Nov 01; 170(5):1787-91. PubMed ID: 14532777
    [Abstract] [Full Text] [Related]

  • 15. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH.
    Eur Urol; 2009 Mar 01; 55(3):563-74. PubMed ID: 19058905
    [Abstract] [Full Text] [Related]

  • 16. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK.
    Eur Urol; 2008 Apr 01; 53(4):750-7. PubMed ID: 17964070
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma.
    Froschermaier SE, Pilarsky CP, Wirth MP.
    Urology; 1996 Apr 01; 47(4):525-8. PubMed ID: 8638361
    [Abstract] [Full Text] [Related]

  • 18. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
    Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, Diamandis EP.
    BJU Int; 2005 Sep 01; 96(4):521-7. PubMed ID: 16104903
    [Abstract] [Full Text] [Related]

  • 19. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
    Chun FK, Hutterer GC, Perrotte P, Gallina A, Valiquette L, Benard F, McCormack M, Briganti A, Ionescu C, Jeldres C, Guay JP, Saad F, Karakiewicz PI.
    BJU Int; 2007 Jul 01; 100(1):37-41. PubMed ID: 17488305
    [Abstract] [Full Text] [Related]

  • 20. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.
    BJU Int; 2012 Jun 01; 109(11):1627-35. PubMed ID: 21939492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.